首页> 外文期刊>Medicinal chemistry research: an international journal for rapid communications on design and mechanisms of action of biologically active agents >Evaluation of phytocannabinoids from high-potency Cannabis sativa using in vitro bioassays to determine structure-activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2
【24h】

Evaluation of phytocannabinoids from high-potency Cannabis sativa using in vitro bioassays to determine structure-activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2

机译:使用体外生物测定法评估高效大麻中的植物大麻素,以确定大麻素受体1和大麻素受体2的结构活性关系

获取原文
获取原文并翻译 | 示例
           

摘要

Cannabis has been around for thousands of years and has been used recreationally, medicinally, and for fiber. Over 500 compounds have been isolated from Cannabis sativa with approximately 105 being cannabi-noids. Of those 105 compounds, DELTA~9-tetrahydrocannabinol has been determined as the primary constituent, which is also responsible for the psychoactivity associated with Cannabis. Cannabinoid receptors belong to the large superfamily of G protein-coupled receptors. Targeting the cannabinoid receptors has the potential to treat a variety of conditions such as pain, neurodegeneration, appetite, immune function, anxiety, cancer, and others. Developing in vitro bioassays to determine binding and functional activity of compounds has the ability to lead researchers to develop a safe and effective drug that may target the cannabinoid receptors. Using radioligand binding and functional bioassays, a structure-activity relationship for major and minor cannabinoids was developed.
机译:大麻已经存在了数千年,并已在娱乐,医学和纤维领域得到广泛使用。从大麻中已分离出500多种化合物,其中约105种是大麻素。在这105种化合物中,已确定DELTA〜9-四氢大麻酚为主要成分,这也与大麻相关的心理活性有关。大麻受体属于G蛋白偶联受体的超家族。靶向大麻素受体具有治疗多种疾病的潜力,例如疼痛,神经变性,食欲,免疫功能,焦虑症,癌症等。开发体外生物测定法以确定化合物的结合和功能活性具有引导研究人员开发可能针对大麻素受体的安全有效药物的能力。使用放射性配体结合和功能生物测定法,开发了主要和次要大麻素的构效关系。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号